TAN-452

Modify Date: 2024-01-11 09:07:59

TAN-452 Structure
TAN-452 structure
Common Name TAN-452
CAS Number 892039-23-5 Molecular Weight 486.56
Density N/A Boiling Point N/A
Molecular Formula C29H30N2O5 Melting Point N/A
MSDS N/A Flash Point N/A

 Use of TAN-452


TAN-452 is an orally active, selective peripherally acting δ-opioid receptor (DOR) antagonist with a Ki of 0.47 nM and a Kb of 0.21 nM. TAN-452 is an antagonist for μ-opioid receptor (MOR; Ki=36.56 nM and Kb=9.43 nM) and κ-opioid receptor (KOR; Ki=5.31 nM and Kb=7.18 nM). TAN-452, a derivative of Naltrindole, demonstrates low brain penetrability and attenuates morphine-induced side effects without affecting pain control[1].

 Names

Name TAN-452

 TAN-452 Biological Activity

Description TAN-452 is an orally active, selective peripherally acting δ-opioid receptor (DOR) antagonist with a Ki of 0.47 nM and a Kb of 0.21 nM. TAN-452 is an antagonist for μ-opioid receptor (MOR; Ki=36.56 nM and Kb=9.43 nM) and κ-opioid receptor (KOR; Ki=5.31 nM and Kb=7.18 nM). TAN-452, a derivative of Naltrindole, demonstrates low brain penetrability and attenuates morphine-induced side effects without affecting pain control[1].
Related Catalog
Target

Ki: 0.47 nM (DOR), 36.56 nM (MOR) and 5.31 nM (KOR)[1] Kb: 0.21 nM (DOR), 9.43 nM (MOR) and 7.18 nM (KOR)[1]

In Vivo TAN-452 (1, 3, 10 mg/kg for p.o. or 0.3, 1, 3 mg/kg for s.c.) suppresses morphine-induced emesis in ferrets[1]. TAN-452 (30 mg/kg/2 mL for PO or 3 mg/kg/mL for IV) has a T1/2 of 2.1 hours[1]. TAN-452 suppresses morphine-induced small intestinal transit (SIT) inhibition in a dose-dependent manner. Administration of TAN-452 at 30 mg/kg alone does not affect SIT[1]. TAN-452 (10, 30 mg/kg; s.c.) significantly suppresses morphine-induced antinociception 30 min after administration. TAN-452 (po) produces no effect up to 300 mg/kg[1]. Animal Model: Male ferrets (1.3-1.9 kg)[1] Dosage: 1, 3, 10 mg/kg (p.o.) or 0.3, 1, 3 mg/kg (s.c.) Administration: PO or SC; before morphine Result: Prevented morphine-induced emesis in half of the animals with orally administered of 1 mg/kg and completely abolished emesis at 3 and 10 mg/kg. Completely abolished emesis by subcutaneous injection at 0.3, 1, and 3 mg/kg. Animal Model: Crj:CD(SD) IGS male rats (7 weeks old)[1] Dosage: 30 mg/kg/2 mL for PO or 3 mg/kg/mL for IV (Pharmacokinetic Analysis) Administration: Orally or intravenously Result: Had a T1/2 of 2.1 hours, a CL of 78.1 mL/min•kg, a Vss of 12.1 L/kg, and a Cmax of 526 ng/mL.
References

[1]. Tsutomu Suzuki, et al. Pharmacological profile of TAN-452, a novel peripherally acting opioid receptor antagonist for the treatment of opioid-induced bowel syndromes. Life Sci. 2018 Dec 15;215:246-252.

 Chemical & Physical Properties

Molecular Formula C29H30N2O5
Molecular Weight 486.56
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.
Top Suppliers:I want be here


Get all suppliers and price by the below link:

TAN-452 suppliers

TAN-452 price

Related Compounds: More...
tan 1142
147527-33-1
(E)-[2-[[(2S,5S)-5-[3-(diaminomethylideneamino)propyl]-1-methyl-3,7-dioxo-1,4-diazepan-2-yl]methyl]hydrazinyl]methylideneurea
128126-47-6
TAN 420C
91700-91-3
(E)-[2-[[(2R,5S)-5-[3-(diaminomethylideneamino)propyl]-1-methyl-3,7-dioxo-1,4-diazepan-2-yl]methyl]hydrazinyl]methylideneurea
128126-46-5
Tan 1030A
126221-76-9
YF-452
1951466-83-3
PA 452
457657-34-0
AB-452
2226178-35-2
Awamycin
87913-35-7
(2S)-3-(dimethylamino)-2-[3-({[(9H-fluoren-9-yl)methoxy]carbonyl}amino)-2-methylpropanamido]propanoic acid
2171322-21-5
4-(dimethylamino)-2-{[3-({[(9H-fluoren-9-yl)methoxy]carbonyl}amino)oxolan-2-yl]formamido}butanoic acid
2171615-70-4
1-[(2S)-3-(dimethylamino)-2-({[(9H-fluoren-9-yl)methoxy]carbonyl}amino)propanoyl]-3-hydroxypyrrolidine-3-carboxylic acid
2171429-36-8
4-[(2S)-3-(dimethylamino)-2-({[(9H-fluoren-9-yl)methoxy]carbonyl}amino)propanamido]hexanoic acid
2171443-52-8
(1RS,3RS)-3-[(2S)-3-(dimethylamino)-2-({[(9H-fluoren-9-yl)methoxy]carbonyl}amino)propanamido]cyclohexane-1-carboxylic acid
2227760-89-4
3-{[(2S)-3-(dimethylamino)-2-({[(9H-fluoren-9-yl)methoxy]carbonyl}amino)propanamido]methyl}oxolane-2-carboxylic acid
2171440-24-5
(2RS,3SR)-3-[(2S)-3-(dimethylamino)-2-({[(9H-fluoren-9-yl)methoxy]carbonyl}amino)propanamido]oxolane-2-carboxylic acid
2227643-86-7
1-[(2S)-3-(dimethylamino)-2-({[(9H-fluoren-9-yl)methoxy]carbonyl}amino)propanoyl]-5-hydroxypiperidine-3-carboxylic acid
2171351-54-3
2-{2-[(2S)-3-(dimethylamino)-2-({[(9H-fluoren-9-yl)methoxy]carbonyl}amino)propanamido]cyclopentyl}acetic acid
2171333-69-8
3-{2-[({[(9H-fluoren-9-yl)methoxy]carbonyl}amino)methyl]butanamido}-2,2,4-trimethylpentanoic acid
2172229-53-5